


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound having the structural formula




wherein

R^1 and R^2 :


β 1

- i) independently represent H or lower alkyl;
- ii) together form a bridge of structure




wherein bonding is achieved via the terminal carbon atoms;

- iii) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms; or

- iv) together form a bridge of structure



wherein one or two ring members T^1 are N and the others are CH, and bonding is

achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 4; and

G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;

- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)₂;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO₂R³;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;

- $-\text{S(O)}_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCON(R}^6\text{)}_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$; and
- $-\text{NR}^3\text{CON(R}^6\text{)}_2$

β 1
 R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

R^4 is H, halogen, or lower alkyl;

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NH;

Y is selected from the group consisting of

- $-(\text{CR}^4_2)_n-\text{S(O)}_p-(5\text{-membered heteroaryl})-(\text{CR}^4_2)_s-$;
- $-(\text{CR}^4_2)_n-\text{C(G}^2\text{)}(\text{R}^4)-(\text{CR}^4_2)_s-$;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G^2 is selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, and $-\text{CH}_2\text{N}(\text{R}^6)_2$;

- $-\text{O}-\text{CH}_2-$;
- $-\text{S}(\text{O})-$;
- $-\text{S}(\text{O})_2-$;
- $-\text{SCH}_2-$;
- $-\text{S}(\text{O})\text{CH}_2-$;
- $-\text{S}(\text{O})_2\text{CH}_2-$;
- $-\text{CH}_2\text{S}(\text{O})-$; and
- $-\text{CH}_2\text{S}(\text{O})_2-$

$\mathcal{P} /$
A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, B, D, E, and L is 1, 2, or 3; and
- b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, or 2;

G^3 is selected from the group consisting of

- lower alkyl;
- $-\text{NR}^3\text{COR}^6$;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- $-\text{OR}^6$;
- $-\text{SR}^6$;
- $-\text{S}(\text{O})\text{R}^6$;

- $-S(O)_2R^6$;
- $-OCOR^6$;
- $-COR^6$;
- $-CO_2R^6$;
- $-CH_2OR^3$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-NO_2$;
- $-CN$;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$ (optionally substituted heteroarylalkyl);
- $-OCON(R^6)_2$;
- $-NR^3CO_2R^6$; and
- $-NR^3CON(R^6)_2$;

J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G⁴ on ring J and is 0, 1, 2, 3, 4, or 5, and

B1
G⁴ moieties are selected from the group consisting of


- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- phenyl lower alkoxycarbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;

B)

- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)₂;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- -OCO₂R³;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);

- -CHO;
- -OCON(R⁶)₂;
- -NR³CO₂R⁶;
- -NR³CON(R⁶)₂; and
- fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:


a)



wherein

each T² independently represents N, CH, or CG⁴;
T³ represents S, O, CR⁴G⁴, C(R⁴)₂, or NR³; and
bonding to ring J is achieved via terminal atoms T² and T³;


b)



wherein

each T² independently represents N, CH, or CG⁴;
with the proviso that a maximum of two bridge atoms T² may be N; and
bonding to ring J is achieved via terminal atoms T²; and

c)



wherein

each T⁴, T⁵, and T⁶ independently represents O, S, CR⁴G⁴, C(R⁴)₂, or NR³;
and

bonding to ring J is achieved via terminal atoms T⁴ or T⁵ ;
with the provisos that:

- i) when one T⁴ is O, S, or NR³, the other T⁴ is CR⁴G⁴ or C(R⁴)₂ ;
- ii) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and
- iii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;


and with the further provisos that:

131

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a heterocycle of 5 – 7 ring atoms; and
- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CHO, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, nitro, amidino, guanidino, mercapto, sulfo, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.


2. (Currently amended) A compound having the structural formula



wherein


R¹ and R² :

i) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and bonding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 2; and

G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;

B1

- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -NO₂;
- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy; and
- -S(O)_p(optionally substituted heteroarylalkyl);

R³ is H or lower alkyl;

R⁶ is independently selected from the group consisting of

- H;
- lower alkyl;

- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

p is 0 or 1;

Y is selected from the group consisting of

- $-(CH_2)_n-S(O)_p-(5\text{-membered heteroaryl})-(CH_2)_s-$;
- $-(CH_2)_n-C(G^2)(H)-(CH_2)_s-$;

wherein

n and s are each independently 0 or 1; and


G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and -CH₂N(R⁶)₂;

- -O-CH₂-;
- -S(O)-;
- -S(O)₂-;
- -SCH₂-;
- -S(O)CH₂-;
- -S(O)₂CH₂-;
- -CH₂S(O)-; and
- -CH₂S(O)₂-

A and D independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, D, and L is 1 or 2; and
- b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, or 2;

Y1
G³ is selected from the group consisting of

- lower alkyl;
- -NR³COR⁶;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -S(O)₂N(R⁶)₂;
- -CN;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy; and
- -S(O)_p(optionally substituted heteroarylalkyl);

q' represents the number of substituents G⁴ on the phenyl ring and is 0, 1, 2, or 3;

and

G⁴ moieties are selected from the group consisting of


- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- halogen-substituted alkyl;

151

- hydroxy-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxycarbonyl-substituted alkyl;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);

- optionally substituted heteroarylalkyloxy;
- S(O)_p(optionally substituted heteroarylalkyl); and
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




wherein

each T² independently represents N, CH, or CG⁴;

T³ represents S, O, CHG⁴, CH₂, or NR³; and

bonding to the phenyl ring is achieved via terminal atoms T² and T³;

b)




wherein

each T² independently represents N, CH, or CG⁴;

with the proviso that a maximum of two bridge atoms T² may be N; and

bonding to the phenyl ring is achieved via terminal atoms T²; and

c)



wherein

each T⁵, and T⁶ independently represents O, S, CHG⁴, CH₂, or NR³; and

bonding to the phenyl ring is achieved via terminal atoms T⁵;

with the provisos that:

- a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and

ii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;


and with the further provisos that:

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a heterocycle of 5 – 7 ring atoms; and

- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, , nitro, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.


3. (Currently amended) A compound having the structural formula



wherein


R¹ and R² :

i) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms, and any group G¹ is located on a non-terminal atom of the bridge; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and bonding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 2; and

131 G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- -OR⁶ wherein R⁶ represents lower alkyl;
- -NO₂;
- optionally substituted heteroaryloxy; and
- optionally substituted heteroarylalkyloxy;

R³ is H or lower alkyl;

R⁶ is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

p is 0 or 1;

Y is selected from the group consisting of

- $-\text{S(O)}_p-(5\text{-membered heteroaryl})-$;
- $-\text{C}(\text{CN})(\text{H})-$;
- $-\text{O-CH}_2-$;
- $-\text{S(O)}-$; and
- $-\text{S(O)}_2-$;

q is 0 or 1;

151

G³ is selected from the group consisting of

- lower alkyl;
- $-\text{NR}^3\text{COR}^6$;
- $-\text{CO}_2\text{R}^6$;
- $-\text{CON}(\text{R}^6)_2$; and
- $-\text{S(O)}_2\text{N}(\text{R}^6)_2$;

q' represents the number of substituents G⁴ on the phenyl ring and is 0, 1, 2, or 3;

and


G⁴ moieties are selected from the group consisting of

- $-\text{N}(\text{R}^6)_2$;
- halogen;
- lower alkyl;
- halogen-substituted lower alkyl;
- $-\text{OR}^6$;
- $-\text{SR}^6$;
- $-\text{S(O)}\text{R}^6$;

15

- $-\text{S}(\text{O})_2\text{R}^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-\text{OCOR}^6$;
- $-\text{COR}^6$;
- $-\text{CO}_2\text{R}$;
- $-\text{CON}(\text{R}^6)_2$;
- $-\text{CH}_2\text{OR}^3$;
- $-\text{NO}_2$;
- $-\text{CN}$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl); and
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




wherein

each T^2 independently represents N, CH, or CG^4 ;

T^3 represents S, O, CHG^4 , CH_2 , or NR^3 ; and

bonding to the phenyl ring is achieved via terminal atoms T^2 and T^3 ;

b)



wherein

each T⁵, and T⁶ independently represents O, S, CHG⁴, CH₂, or NR³; and bonding to the phenyl ring is achieved via terminal atoms T⁵; with the provisos that:

- i) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;

and with the further provisos that:

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a heterocycle of 5 – 6 ring atoms; and

- when an aryl, heteroaryl, or heterocycl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, -CO₂R³ , -CON(R⁶)₂ , nitro, and cyano;


or a pharmaceutically acceptable salt or prodrug thereof.

4. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

5. (Previously Amended) A method of treating a mammal having a condition of tumor growth, retinopathy, rheumatoid arthritis, psoriasis, or a bullous disorder associated with subepidermal blister formation, comprising administering to said mammal an amount of a compound of claim 1 which is effective to treat said condition.

6. (cancelled)


7. (Currently amended) A compound having the structural formula



wherein


R¹ and R² :

- i) independently represent H or lower alkyl;
- ii) together form a bridge of structure




wherein bonding is achieved via the terminal carbon atoms;

- iii) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms; or

- iv) together form a bridge of structure



wherein one or two ring members T¹ are N and the others are CH, and bonding is achieved via the terminal atoms; and
wherein

m is 0 or an integer 1 – 4; and

β1
G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;

131

- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- phenyl-lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)₂;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;

- $-\text{OCO}_2\text{R}^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$; and
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$

b1
R³ is H or lower alkyl;

R⁶ is independently selected from the group consisting of

- H;
- alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

R⁴ is H, halogen, or lower alkyl;

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NH;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH or OAcyl;
- $-\text{CH}_2\text{O}-$;

- $-\text{CH}_2\text{S}-$;
- $-\text{CH}_2\text{NH}-$;
- $-\text{O}-$;
- $-\text{S}-$;
- $-\text{NH}-$;
- $-(\text{CR}^4_2)_n\text{S(O)}_p-(5\text{-membered heteroaryl})-(\text{CR}^4_2)_s-$;
- $-(\text{CR}^4_2)_n\text{C(G}^2\text{)(R}^4\text{)}-(\text{CR}^4_2)_s-$;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G^2 is selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, and $-\text{CH}_2\text{N}(\text{R}^6)_2$;

b1

- $-\text{O-CH}_2-$;
- $-\text{S(O)}-$;
- $-\text{S(O)}_2-$;
- $-\text{SCH}_2-$;
- $-\text{S(O)CH}_2-$;
- $-\text{S(O)}_2\text{CH}_2-$;
- $-\text{CH}_2\text{S(O)}-$; and
- $-\text{CH}_2\text{S(O)}_2-$

A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, B, D, E, and L is 1, 2, or 3; and
- b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, 1 or 2;

b1
G³ is selected from the group consisting of

- -NR³COR⁶;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CH₂OR³;
- -CON(R⁶)₂;
- -S(O)₂N(R⁶)₂;
- -NO₂;
- -CN;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- -OCON(R⁶)₂;
- -NR³CO₂R⁶; and

- $-\text{NR}^3\text{CON}(\text{R}^6)_2$;

J is a ring selected from the group consisting of

- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G^4 on ring J and is 0, 1, 2, 3, 4, or 5, and

G^4 moieties are selected from the group consisting of

- $-\text{N}(\text{R}^6)_2$;
- $-\text{NR}^3\text{COR}^6$;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;
- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;


B1

- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- amidino;
- guanidino;
- sulfo;
- -B(OH)₂;
- optionally substituted aryl;
- optionally substituted heteroaryl;

131

- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- $-\text{OCO}_2\text{R}^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S(O)}_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$;
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$; and
- fused ring-forming bridges attached to and connecting adjacent positions of ring J, said bridges having the structures:

a)




wherein

each T² independently represents N, CH, or CG⁴;

T³ represents S, O, CR⁴G⁴, C(R⁴)₂, or NR³; and

bonding to ring J is achieved via terminal atoms T² and T³;

b)




wherein

each T² independently represents N, CH, or CG⁴;

with the proviso that a maximum of two bridge atoms T² may be N ; and

bonding to ring J is achieved via terminal atoms T²; and

c)



wherein

each T⁴, T⁵, and T⁶ independently represents O, S, CR⁴G⁴, C(R⁴)₂, or NR³;

and

bonding to ring J is achieved via terminal atoms T⁴ or T⁵;

with the provisos that:

B1


- i) when one T⁴ is O, S, or NR³, the other T⁴ is CR⁴G⁴ or C(R⁴)₂;
- ii) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and
- iii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;

and with the further provisos that:

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a heterocycle of 5 – 7 ring atoms; and
- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CHO, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, nitro, amidino, guanidino, mercapto, sulfo, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.


8. (Currently amended) A compound having the structural formula



wherein


R¹ and R² :

i) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and bonding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 2; and

G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;

B1

- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -NO₂;
- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy; and
- -S(O)_p(optionally substituted heteroarylalkyl);

R³ is H or lower alkyl;

R⁶ is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

p is 0 or 1;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH or OAcyl;
- -CH₂-O- ;
- -CH₂-S- ;
- -CH₂-NH- ;
- -O- ;
- -S- ;
- -NH- ;
- -(CH₂)_n-S(O)_p-(5-membered heteroaryl)-(CH₂)_s-;
- -(CH₂)_n-C(G²)(H)-(CH₂)_s- ;

wherein

n and s are each independently 0 or 1; and

G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and -

CH₂N(R⁶)₂ ;

- -O-CH₂- ;
- -S(O)- ;
- -S(O)₂- ;
- -SCH₂- ;
- -S(O)CH₂- ;
- -S(O)₂CH₂- ;

- $-\text{CH}_2\text{S(O)}-$; and
- $-\text{CH}_2\text{S(O)}_2-$

A and D independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, D, and L is 1 or 2; and
- b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, 1 or 2;

G^3 is selected from the group consisting of

- $-\text{NR}^3\text{COR}^6;$
- $-\text{OR}^6;$
- $-\text{SR}^6;$
- $-\text{S(O)R}^6;$
- $-\text{S(O)}_2\text{R}^6;$
- $-\text{CO}_2\text{R}^6;$
- $-\text{CON}(\text{R}^6)_2;$
- $-\text{S(O)}_2\text{N}(\text{R}^6)_2;$
- $-\text{CN};$
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S(O)}_p(\text{optionally substituted heteroaryl});$
- optionally substituted heteroarylalkyloxy; and
- $-\text{S(O)}_p(\text{optionally substituted heteroarylalkyl});$

q' represents the number of substituents G⁴ on the phenyl ring and is 0, 1, 2, or 3;

and


G⁴ moieties are selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- halogen-substituted alkyl;
- hydroxy-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;

β |

- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -CH₂OR³;
- -NO₂;
- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl); and
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




wherein

each T² independently represents N, CH, or CG⁴;

T³ represents S, O, CHG⁴, C(H)₂, or NR³; and

bonding to the phenyl ring is achieved via terminal atoms T² and T³;

b)




wherein

each T² independently represents N, CH, or CG⁴;

with the proviso that a maximum of two bridge atoms T² may be N; and

bonding to the phenyl ring is achieved via terminal atoms T²; and

c)



wherein

each T⁵, and T⁶ independently represents O, S, CHG⁴, C(H)₂, or NR³; and bonding to the phenyl ring is achieved via terminal atoms T⁵;

with the provisos that:


- i) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;

and with the further provisos that:

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a heterocycle of 5 – 7 ring atoms; and
- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, nitro, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.


9. (Currently amended) A compound having the structural formula



wherein


R¹ and R²:

i) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms, and any group G¹ is located on a non-terminal atom of the bridge; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and bonding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 2; and

G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- -OR⁶ wherein R⁶ represents lower alkyl;
- -NO₂;
- optionally substituted heteroaryloxy; and

- optionally substituted heteroarylalkyloxy;

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

β } p is 0 or 1;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH;
- $-CH_2-O-$;
- $-S-$;
- $-NH-$;
- $-S(O)_p-(5\text{-membered heteroaryl})-$;
- $-C(CN)(H)-$;
- $-O-CH_2-$;
- $-S(O)-$; and
- $-S(O)_2-$;

q is 0 or 1;

G^3 is selected from the group consisting of

- $-NR^3COR^6$;
- $-CO_2R^6$;

- $-\text{CON}(\text{R}^6)_2$; and
- $-\text{S}(\text{O})_2\text{N}(\text{R}^6)_2$;

q' represents the number of substituents G^4 on the phenyl ring and is 0, 1, 2, or 3;


and

G^4 moieties are selected from the group consisting of

- $-\text{N}(\text{R}^6)_2$;
- halogen;
- lower alkyl;
- halogen-substituted lower alkyl;
- $-\text{OR}^6$;
- $-\text{SR}^6$;
- $-\text{S}(\text{O})\text{R}^6$;
- $-\text{S}(\text{O})_2\text{R}^6$;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- $-\text{OCOR}^6$;
- $-\text{COR}^6$;
- $-\text{CO}_2\text{R}^6$;
- $-\text{CON}(\text{R}^6)_2$;
- $-\text{CH}_2\text{OR}^3$;
- $-\text{NO}_2$;
- $-\text{CN}$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;

- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl); and
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)



wherein


each T^2 independently represents N, CH, or CG^4 ;

T^3 represents S, O, CHG^4 , CH_2 , or NR^3 ; and

bonding to the phenyl ring is achieved via terminal atoms T^2 and T^3 ;

B1

b)



wherein

each T^5 , and T^6 independently represents O, S, CHG^4 , CH_2 , or NR^3 ; and

bonding to the phenyl ring is achieved via terminal atoms T^5 ;

with the provisos that:

- i) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;

and with the further provisos that:

- in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a heterocycle of 5 – 6 ring atoms; and


- when an aryl, heteroaryl, or heterocyclyl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, $-\text{CO}_2\text{R}^3$, $-\text{CON}(\text{R}^6)_2$, nitro, and cyano;
or a pharmaceutically acceptable salt or prodrug thereof.

10. (Original) A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.

11. (Previously Amended) A method of treating a mammal having a condition of tumor growth, retinopathy, rheumatoid arthritis, psoriasis, or a bullous disorder associated with subepidermal blister formation, comprising administering to said mammal an amount of a compound of claim 7 which is effective to treat said condition.

12. (cancelled)


13. (Currently amended) A compound having the structural formula



wherein


R^1 and R^2 :

- i) independently represent H or lower alkyl;
- ii) together form a bridge of structure




wherein bonding is achieved via the terminal carbon atoms;

iii) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms; or

iv) together form a bridge of structure



wherein one or two ring members T¹ are N and the others are CH, and bonding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 4; and

G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- cycloalkyl;
- lower alkenyl;
- lower cycloalkenyl;
- halogen-substituted alkyl;
- amino-substituted alkyl;
- N-lower alkylamino-substituted alkyl;

- N,N-di-lower alkylamino-substituted alkyl;
- N-lower alkanoylamino-substituted alkyl;
- hydroxy-substituted alkyl;
- cyano-substituted alkyl;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- phenyl lower alkoxy carbonyl-substituted alkyl;
- halogen-substituted alkylamino;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;
- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- cyano-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxy carbonyl-substituted alkylamino;
- phenyl-lower alkoxy carbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;

17

- $-\text{CH}_2\text{OR}^3$;
- $-\text{NO}_2$;
- $-\text{CN}$;
- amidino;
- guanidino;
- sulfo;
- $-\text{B}(\text{OH})_2$;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- $-\text{OCO}_2\text{R}^3$;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl);
- $-\text{CHO}$;
- $-\text{OCON}(\text{R}^6)_2$;
- $-\text{NR}^3\text{CO}_2\text{R}^6$; and
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- alkyl;
- optionally substituted aryl;

- optionally substituted aryl lower alkyl; and

R^4 is H, halogen, or lower alkyl;

p is 0, 1, or 2;

X is selected from the group consisting of O, S, and NH;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH or OAcyl;
- $-CH_2-O-$;
- $-CH_2-S-$;
- $-CH_2-NH-$;
- $-O-$;
- $-S-$;
- $-NH-$;
- $-(CR^4_2)_n-S(O)_p-(5\text{-membered heteroaryl})-(CR^4_2)_s-$;
- $-(CR^4_2)_n-C(G^2)(R^4)-(CR^4_2)_s-$;

wherein

n and s are each independently 0 or an integer of 1 – 2; and

G^2 is selected from the group consisting of $-CN$, $-CO_2R^3$, $-CON(R^6)_2$, and –

$CH_2N(R^6)_2$;

- $-O-CH_2-$;
- $-S(O)-$;
- $-S(O)_2-$;
- $-SCH_2-$;
- $-S(O)CH_2-$;
- $-S(O)_2CH_2-$;

- $-\text{CH}_2\text{S}(\text{O})-$; and
- $-\text{CH}_2\text{S}(\text{O})_2-$

A and D independently represent N or CH;

B and E independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, B, D, E, and L is 1, 2, or 3; and
- b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, or 2;

*G*³ is selected from the group consisting of

- lower alkyl;
- $-\text{NR}^3\text{COR}^6$;
- carboxy-substituted alkyl;
- lower alkoxy carbonyl-substituted alkyl;
- $-\text{OR}^6$;
- $-\text{SR}^6$;
- $-\text{S}(\text{O})\text{R}^6$;
- $-\text{S}(\text{O})_2\text{R}^6$;
- $-\text{OCOR}^6$;
- $-\text{COR}^6$;
- $-\text{CO}_2\text{R}^6$;
- $-\text{CH}_2\text{OR}^3$;
- $-\text{CON}(\text{R}^6)_2$;
- $-\text{S}(\text{O})_2\text{N}(\text{R}^6)_2$;
- $-\text{NO}_2$;

- -CN;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted saturated heterocyclyl;
- optionally substituted partially unsaturated heterocyclyl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- -OCON(R⁶)₂;
- -NR³CO₂R⁶; and
- -NR³CON(R⁶)₂;

J is a ring selected from the group consisting of


- aryl;
- pyridyl; and
- cycloalkyl;

q' represents the number of substituents G⁴ on ring J and is 0, 1, 2, 3, 4, or 5, and G⁴ moieties are selected from the group consisting of

- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- -S(O)_p(optionally substituted heteroarylalkyl);
- -CHO;
- -OCON(R⁶)₂;

- $-\text{NR}^3\text{CO}_2\text{R}^6$; and
- $-\text{NR}^3\text{CON}(\text{R}^6)_2$
- fused ring-forming bridges attached to and connecting adjacent positions of ring J,
said bridges having the structures:


a)



wherein

each T^2 independently represents N, CH, or CG^4 ;
 T^3 represents S, O, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ; and
bonding to ring J is achieved via terminal atoms T^2 and T^3 ;


b)



wherein

each T^2 independently represents N, CH, or CG^4 ;
with the proviso that a maximum of two bridge atoms T^2 may be N; and
bonding to ring J is achieved via terminal atoms T^2 ; and

c)



wherein

each T^4 , T^5 , and T^6 independently represents O, S, CR^4G^4 , $\text{C}(\text{R}^4)_2$, or NR^3 ;
and
bonding to ring J is achieved via terminal atoms T^4 or T^5 ;
with the provisos that:

- i) when one T^4 is O, S, or NR^3 , the other T^4 is CR^4G^4 or $C(R^4)_2$;
- ii) a bridge comprising T^5 and T^6 atoms may contain a maximum of two heteroatoms O, S, or N; and
- iii) in a bridge comprising T^5 and T^6 atoms, when one T^5 is O, the other T^5 is S, CR^4G^4 , $C(R^4)_2$ or NR^3 ;
- iv) in a bridge comprising T^5 and T^6 atoms, when one T^5 group and one T^6 group are O atoms, or two T^6 groups are O atoms, said O atoms are separated by at least one carbon atom;


and with the further provisos that:

β)

- in G^1 , G^2 , G^3 , and G^4 , when two groups R^6 are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR^3 to form a heterocycle of 5 – 7 ring atoms; and
- when an aryl, heteroaryl, or heterocycl ring is optionally substituted, that ring may bear up to 5 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, $-CO_2R^3$, $-CHO$, $-CH_2OR^3$, $-OCO_2R^3$, $-CON(R^6)_2$, $-OCO N(R^6)_2$, $-NR^3CON(R^6)_2$, nitro, amidino, guanidino, mercapto, sulfo, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.


14. (Currently amended) A compound having the structural formula



wherein


R¹ and R²:

i) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and bonding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 2; and

G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- alkyl;
- amino-substituted alkylamino;
- N-lower alkylamino-substituted alkylamino;
- N,N-di-lower alkylamino-substituted alkylamino;

- N-lower alkanoylamino-substituted alkylamino;
- hydroxy-substituted alkylamino;
- carboxy-substituted alkylamino;
- lower alkoxycarbonyl-substituted alkylamino;
- -OR⁶;
- -SR⁶;
- -S(O)R⁶;
- -S(O)₂R⁶;
- halogenated lower alkoxy;
- halogenated lower alkylthio;
- halogenated lower alkylsulfonyl;
- -OCOR⁶;
- -COR⁶;
- -CO₂R⁶;
- -CON(R⁶)₂;
- -NO₂;
- -CN;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- -S(O)_p(optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy; and
- -S(O)_p(optionally substituted heteroarylalkyl);

R³ is H or lower alkyl;

R⁶ is independently selected from the group consisting of

- H;
- lower alkyl;

- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

p is 0 or 1;

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH or OAcyl;
- -CH₂-O- ;
- -CH₂-S- ;
- -CH₂-NH- ;
- -O- ;
- -S- ;
- -NH- ;
- -(CH₂)_n-S(O)_p-(5-membered heteroaryl)-(CH₂)_s-;
- -(CH₂)_n-C(G²)(H)-(CH₂)_s- ;

wherein

n and s are each independently 0 or 1; and

G² is selected from the group consisting of -CN, -CO₂R³, -CON(R⁶)₂, and -CH₂N(R⁶)₂;

- -O-CH₂- ;
- -S(O)- ;
- -S(O)₂- ;
- -SCH₂- ;
- -S(O)CH₂- ;
- -S(O)₂CH₂- ;
- -CH₂S(O)- ; and
- -CH₂S(O)₂-

A and D independently represent N or CH;

L represents N or CH;

with the provisos that

- a) the total number of N atoms in the ring containing A, D, and L is 1 or 2; and
- b) when L represents CH, at least one of A and D is an N atom;

q is 0, 1, or 2;

G^3 is selected from the group consisting of

- lower alkyl;
- $-NR^3COR^6$;
- $-OR^6$;
- $-SR^6$;
- $-S(O)R^6$;
- $-S(O)_2R^6$;
- $-CO_2R^6$;
- $-CON(R^6)_2$;
- $-S(O)_2N(R^6)_2$;
- $-CN$;
- optionally substituted aryl;
- optionally substituted heteroaryl;
- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy; and
- $-S(O)_p$ (optionally substituted heteroarylalkyl);


q' represents the number of substituents G^4 on the phenyl ring and is 0, 1, 2, or 3;

and

G^4 moieties are selected from the group consisting of

- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-S(O)_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-S(O)_p$ (optionally substituted heteroarylalkyl); and
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




wherein

each T^2 independently represents N, CH, or CG^4 ;

T^3 represents S, O, CHG^4 , $C(H)_2$, or NR^3 ; and

bonding to the phenyl ring is achieved via terminal atoms T^2 and T^3 ;

b)




wherein

each T^2 independently represents N, CH, or CG^4 ;

with the proviso that a maximum of two bridge atoms T^2 may be N; and

bonding to the phenyl ring is achieved via terminal atoms T^2 ; and

c)



wherein

each T⁵, and T⁶ independently represents O, S, CHG⁴, CH₂, or NR³; and bonding to the phenyl ring is achieved via terminal atoms T⁵; with the provisos that:

- i) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ is O, the other T⁵ is S, CHG⁴, CH₂ or NR³;
- iii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;


and with the further provisos that:

B (

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a heterocycle of 5 – 7 ring atoms; and
- when an aryl, heteroaryl, or heterocycl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, lower alkanoyloxy, -CO₂R³, -CH₂OR³, -OCO₂R³, -CON(R⁶)₂, -OCO N(R⁶)₂, -NR³CON(R⁶)₂, nitro, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.


15. (Currently amended) A compound having the structural formula



wherein


R¹ and R²:

i) together form a bridge of structure



wherein bonding is achieved via the terminal carbon atoms, and any group G¹ is located on a non-terminal atom of the bridge; or

ii) together form a bridge of structure



wherein one of the ring members T¹ is N and the others are CH, and bonding is achieved via the terminal atoms; and

wherein

m is 0 or an integer 1 – 2; and

G¹ is a substituent independently selected from the group consisting of

- -N(R⁶)₂;
- -NR³COR⁶;
- halogen;
- -OR⁶ wherein R⁶ represents lower alkyl;
- -NO₂;
- optionally substituted heteroaryloxy; and

- optionally substituted heteroarylalkyloxy;

R^3 is H or lower alkyl;

R^6 is independently selected from the group consisting of

- H;
- lower alkyl;
- optionally substituted aryl;
- optionally substituted aryl lower alkyl; and

p is 0 or 1;

Y

Y is selected from the group consisting of

- lower alkylene, optionally substituted by OH;
- $-\text{CH}_2\text{O}-$;
- $-\text{S}-$;
- $-\text{NH}-$;
- $-\text{S}(\text{O})_p-(5\text{-membered heteroaryl})-$;
- $-\text{C}(\text{CN})(\text{H})-$;
- $-\text{O}-\text{CH}_2-$;
- $-\text{S}(\text{O})-$; and
- $-\text{S}(\text{O})_2-$;

q is 0 or 1;

G^3 is selected from the group consisting of

- lower alkyl;
- $-\text{NR}^3\text{COR}^6$;


- $-\text{CO}_2\text{R}^6$;
- $-\text{CON}(\text{R}^6)_2$; and
- $-\text{S}(\text{O})_2\text{N}(\text{R}^6)_2$;

q' represents the number of substituents G^4 on the phenyl ring, and is 0, 1, 2, or 3;
and

G^4 moieties are selected from the group consisting of

- optionally substituted heteroarylalkyl;
- optionally substituted heteroaryloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroaryl);
- optionally substituted heteroarylalkyloxy;
- $-\text{S}(\text{O})_p$ (optionally substituted heteroarylalkyl); and
- fused ring-forming bridges attached to and connecting adjacent positions of the phenyl ring, said bridges having the structures:

a)




wherein

each T^2 independently represents N, CH, or CG^4 ;

T^3 represents S, O, CHG^4 , CH_2 , or NR^3 ; and

bonding to the phenyl ring is achieved via terminal atoms T^2 and T^3 ;

b)



wherein

each T^5 , and T^6 independently represents O, S, CHG^4 , CH_2 , or NR^3 ; and
bonding to the phenyl ring is achieved via terminal atoms T^5 ;

with the provisos that:

- i) a bridge comprising T⁵ and T⁶ atoms may contain a maximum of two heteroatoms O, S, or N; and
- ii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ is O, the other T⁵ is S, CR⁴G⁴, C(R⁴)₂ or NR³;
- iii) in a bridge comprising T⁵ and T⁶ atoms, when one T⁵ group and one T⁶ group are O atoms, or two T⁶ groups are O atoms, said O atoms are separated by at least one carbon atom;

and with the further provisos that:

B1

- in G¹, G², G³, and G⁴, when two groups R⁶ are each alkyl and located on the same N atom they may be linked by a bond, an O, an S, or NR³ to form a heterocycle of 5 – 6 ring atoms; and
- when an aryl, heteroaryl, or heterocycl ring is optionally substituted, that ring may bear up to 2 substituents which are independently selected from the group consisting of amino, mono-loweralkyl-substituted amino, di-loweralkyl-substituted amino, lower alkanoylamino, halogeno, lower alkyl, halogenated lower alkyl, hydroxy, lower alkoxy, lower alkylthio, halogenated lower alkoxy, halogenated lower alkylthio, -CO₂R³ , -CON(R⁶)₂ , nitro, and cyano;

or a pharmaceutically acceptable salt or prodrug thereof.

16. (Original) A pharmaceutical composition comprising a compound of claim 13 and a pharmaceutically acceptable carrier.

17. (Previously Amended) A method of treating a mammal having a condition of tumor growth, retinopathy, rheumatoid arthritis, psoriasis, or a bullous disorder associated with

subepidermal blister formation, comprising administering to said mammal an amount of a compound of claim 13 which is effective to treat said condition.

18. (Cancelled)

19. (Previously Amended) A compound selected from the group consisting of:

15 (

- a) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide;
- b) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide;
- c) 1-(4-chlorophenylamino)-4-(3-pyridylmethoxy)phthalazine;
- d) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid methylamide;
- e) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid amide;
- f) 4-[4-(3-Bromophenylamino)phthalazin-1-ylmethyl]-pyridin-2-yl carboxylic acid methylamide;
- g) 4-[4-(3-Bromophenylamino)phthalazin-1-ylmethyl]-pyridin-2-yl carboxylic acid amide;
- h) 1-(4-chlorophenylamino)-4-[(2-phenyl-4-pyridyl)methyl]phthalazine;
- i) 1-[4-(4-pyridyloxy)phenylamino]-4-(4-pyridylmethyl)phthalazine;
- j) 1-(indan-5-ylamino)-4-(4-pyridylmethyl)phthalazine;
- k) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide dihydrochloride;
- l) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid methylamide dimethanesulfonate;
- m) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide dihydrochloride;
- n) 4-[4-(4-Chlorophenylamino)phthalazin-1-ylmethyl]pyridin-2-yl carboxylic acid amide dimethanesulfonate;
- o) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid amide dihydrochloride;

- p) 4-[4-(4-Chlorophenylamino)phthalazin-1-yloxymethyl]pyridin-2-yl carboxylic acid amide dimethanesulfonate;
- q) 1-(4-chlorophenylamino)-4-[5-(4-pyridyl)-1H-1,2,4-triazolyl-3-ylthio]phthalazine;
- r) 1-(4-isopropylphenylamino)-4-[5-(4-pyridyl)-1H-1,2,4-triazolyl-3-ylthio]phthalazine
- s) 1-(4-chlorophenylamino)-4-(4-pyridylsufonyl)phthalazine;
- t) 1-(4-chlorophenylamino)-4-(4-pyridylsufinyl)phthalazine;
- v) 1-(indan-5-ylamino)-4-(4-pyridylcyanomethyl)phthalazine; and
- w) 1-(benzothiazol-6-ylamino)-4-(4-pyridylcyanomethyl)phthalazine.

20. (Previously added) The method of claim 5, wherein said condition of retinopathy is diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, or age-related macular degeneration.

21. (Previously added) The method of claim 5, wherein when said condition is a bullous disorder associated with subepidermal blister formation, it is bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis.

22. (Previously added) The method of claim 11, wherein said condition of retinopathy is diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, or age-related macular degeneration.

23. (Previously added) The method of claim 11, wherein when said condition is a bullous disorder associated with subepidermal blister formation, it is bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis.

24. (Previously added) The method of claim 17, wherein said condition of retinopathy is diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, or age-related macular degeneration.

Bl
25. (Previously added) The method of claim 17, wherein when said condition is a bullous disorder associated with subepidermal blister formation, it is bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis.
